He Yuxian, Barker Sophie J, MacDonald Angus J, Yu Yu, Cao Long, Li Jingjing, Parhar Ranjit, Heck Susanne, Hartmann Susanne, Golenbock Douglas T, Jiang Shibo, Libri Nathan A, Semper Amanda E, Rosenberg William M, Lustigman Sara
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.
J Immunol. 2009 Apr 1;182(7):4005-16. doi: 10.4049/jimmunol.0800531.
We previously reported that rOv-ASP-1, a recombinant Onchocerca volvulus activation associated protein-1, was a potent adjuvant for recombinant protein or synthetic peptide-based Ags. In this study, we further evaluated the adjuvanticity of rOv-ASP-1 and explored its mechanism of action. Consistently, recombinant full-length spike protein of SARS-CoV or its receptor-binding domain in the presence of rOv-ASP-1 could effectively induce a mixed but Th1-skewed immune response in immunized mice. It appears that rOv-ASP-1 primarily bound to the APCs among human PBMCs and triggered Th1-biased proinflammatory cytokine production probably via the activation of monocyte-derived dendritic cells and the TLR, TLR2, and TLR4, thus suggesting that rOv-ASP-1 is a novel potent innate adjuvant.
我们之前报道过，重组盘尾丝虫激活相关蛋白-1（rOv-ASP-1）是基于重组蛋白或合成肽的抗原的有效佐剂。在本研究中，我们进一步评估了rOv-ASP-1的佐剂活性并探究其作用机制。同样，在rOv-ASP-1存在的情况下，严重急性呼吸综合征冠状病毒（SARS-CoV）的重组全长刺突蛋白或其受体结合结构域能够在免疫小鼠中有效诱导混合但偏向Th1的免疫反应。rOv-ASP-1似乎主要与人外周血单核细胞（PBMCs）中的抗原呈递细胞（APCs）结合，并可能通过激活单核细胞来源的树突状细胞以及Toll样受体（TLR）、TLR2和TLR4触发偏向Th1的促炎细胞因子产生，因此表明rOv-ASP-1是一种新型有效的天然佐剂。
